Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:58:27 EDT Wed 24 Apr 2024
Enter Symbol
or Name
USA
CA



News for C:CYBN from 2023-04-25 to 2024-04-24 - 70 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2024-04-18 13:00C:CYBNCybin Inc0.51News ReleaseCybin publishes CYB210010 research manuscript
2024-04-16 12:27C:CYBNCybin Inc0.51News ReleaseCybin receives depressive disorder therapy patent
2024-04-08 07:12C:CYBNCybin Inc0.55In the NewsGlobe says MindMed, Cybin get nod from U.S. FDA
2024-03-19 12:42C:CYBNCybin Inc0.61News ReleaseCybin closes $150-million (U.S.) private placement
2024-03-15 09:12C:CYBNCybin Inc0.61News ReleaseCybin begins phase 2 CYB004 study for GAD treatment
2024-03-14 11:30C:CYBNCybin Inc0.58News ReleaseCybin talks CYB003 phase 2 FDA meeting, phase 3 design
2024-03-13 09:16C:CYBNCybin Inc0.58News ReleaseCybin arranges $150-million (U.S.) private placement
2024-03-13 08:59C:CYBNCybin Inc0.57News ReleaseCybin's CYB003 receives FDA breakthrough designation
2024-03-12 23:17C:CYBNCybin Inc0.58News ReleaseCybin to host call March 13 for CYB003 update
2024-02-14 12:40C:CYBNCybin Inc0.475News ReleaseCybin has cash of $39-million at Dec. 31
2024-02-14 07:40C:CYBNCybin Inc0.475SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-14 07:34C:CYBNCybin Inc0.475SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-07 11:55C:CYBNCybin Inc0.395News ReleaseCybin receives two patents in Japan for DMT program
2024-01-23 09:05C:CYBNCybin Inc0.485News ReleaseCybin receives FDA OK to begin phase 2a CYB004 study
2024-01-08 11:46C:CYBNCybin Inc0.54News ReleaseCybin says CYB004, SPL028 well tolerated in phase 1
2024-01-04 10:54C:CYBNCybin Inc0.52News ReleaseCybin outlines phase 2 CYB003 results in MDD
2023-12-06 10:41C:CYBNCybin Inc0.57News ReleaseCybin receives U.S. patent for CYB003 program
2023-11-30 10:34C:CYBNCybin Inc0.64News ReleaseCybin boasts about CYB003 phase 2 safety, efficacy data
2023-11-16 12:46C:CYBNCybin Inc0.60News ReleaseCybin to release phase 2 CYB003 data Nov. 30
2023-11-14 19:32C:CYBNCybin Inc0.62News ReleaseCybin has cash of $18.1-million at Sept. 30
2023-11-14 19:07C:CYBNCybin Inc0.62SEDAR Interim MD & ASEDAR Interim MD & A
2023-11-14 19:04C:CYBNCybin Inc0.62SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-14 15:36C:CYBNCybin Inc0.62News ReleaseCybin closes $30-million (U.S.) offering
2023-11-13 17:56C:CYBNCybin Inc0.65Prospectus ApprovedCybin to list up to 66,666,667 more shares on Neo
2023-11-10 09:18C:CYBNCybin Inc0.70News ReleaseCybin arranges $30M (U.S.) offering of units
2023-11-10 08:17C:CYBNCybin Inc0.70Resume TradingCybin resuming at the open
2023-11-10 08:10C:CYBNCybin Inc0.70Halt TradingCybin halted at the open
2023-11-01 12:52C:CYBNCybin Inc0.91News ReleaseCybin plans four clinical studies for 2024
2023-10-31 11:22C:CYBNCybin Inc0.91News ReleaseCybin's CYB003 meets three-week efficacy end point
2023-10-26 09:56C:CYBNCybin Inc0.76News ReleaseCybin receives European patent for deuterated programs
2023-10-25 10:02C:CYBNCybin Inc0.62News ReleaseCybin receives two U.S. patents for deuterated DMT
2023-10-23 18:20C:CYBNCybin Inc0.64SEDAR Early Warning ReportSEDAR Early Warning Report
2023-10-23 12:47C:CYBNCybin Inc0.64News ReleaseCybin closes acquisition of Small Pharma
2023-10-17 17:54C:CYBNCybin Inc0.70News ReleaseCybin's Small Pharma acquisition has court approval
2023-10-12 17:05C:CYBNCybin Inc0.81News ReleaseCybin shareholders approve AGM resolutions
2023-10-03 10:20C:CYBNCybin Inc0.78News ReleaseCybin completes dosing in phase 2 CYB003 study
2023-09-27 11:33C:CYBNCybin Inc0.79News ReleaseCybin target Small Pharma talks phase Ib study data
2023-09-26 10:17C:CYBNCybin Inc0.79News ReleaseCybin signs deal with Fluence for Embark training
2023-09-21 17:11C:CYBNCybin Inc0.65News ReleaseCybin to hold AGM virtually on Oct. 12 at 1 p.m. ET
2023-09-21 10:04C:CYBNCybin Inc0.65News ReleaseCybin completes enrolment for CYB003 phase 2 study
2023-09-05 11:17C:CYBNCybin Inc0.42News ReleaseCybin receives U.S. patent for deuterated tryptamines
2023-08-28 11:02C:CYBNCybin Inc0.40News ReleaseCybin to acquire Small Pharma
2023-08-28 10:59C:CYBNCybin Inc0.415Resume TradingCybin to resume at 8:05 a.m. PT
2023-08-28 09:18C:CYBNCybin Inc0.415Halt TradingCybin halted at the open
2023-08-24 00:50C:CYBNCybin Inc0.405News ReleaseCybin renews $35-million (U.S.) at-the-market program
2023-08-17 10:33C:CYBNCybin Inc0.44News ReleaseCybin prepares for GMP production of CYB003 capsules
2023-08-15 10:07C:CYBNCybin Inc0.44News ReleaseCybin receives U.S. patent for psilocybin analogue
2023-08-14 14:11C:CYBNCybin Inc0.43News ReleaseCybin has $9.3-million in cash at June 30
2023-08-14 07:33C:CYBNCybin Inc0.43SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-04 12:49C:CYBNCybin Inc0.395News ReleaseCybin closes $8.25-million (U.S.) public offering
2023-08-02 11:54C:CYBNCybin Inc0.37News ReleaseCybin starts dosing last cohort of phase 2 CYB003 trial
2023-08-01 11:48C:CYBNCybin Inc0.40News ReleaseCybin prices $8.25-million (U.S.) unit offering
2023-07-31 19:36C:CYBNCybin Inc0.49News ReleaseCybin arranges overnight marketed public unit offering
2023-07-26 10:58C:CYBNCybin Inc0.53News ReleaseCybin forms partnership with Worldwide for CYB003
2023-07-24 10:57C:CYBNCybin Inc0.53News ReleaseCybin completes cohort 5 dosing in CYB003 MDD study
2023-07-20 17:16C:CYBNCybin Inc0.50News ReleaseCybin applauds Kernel's paper on ketamine
2023-07-20 14:44C:CYBNCybin Inc0.52News ReleaseCybin talks fNIRS human neuroimaging study by Kernel
2023-07-12 11:57C:CYBNCybin Inc0.56News ReleaseCybin begins development of EmbarkCT training program
2023-06-29 17:34C:CYBNCybin Inc0.47News ReleaseCybin appoints Bartlone as COO
2023-06-27 17:31C:CYBNCybin Inc0.43News ReleaseCybin has cash of $16.6-million on March 31
2023-06-27 17:08C:CYBNCybin Inc0.43SEDAR MD & ASEDAR MD & A
2023-06-27 17:06C:CYBNCybin Inc0.43SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2023-06-27 17:04C:CYBNCybin Inc0.43SEDAR Annual Information FormSEDAR Annual Information Form
2023-06-27 12:49C:CYBNCybin Inc0.395News ReleaseCybin appoints Climan as adviser
2023-06-16 14:59C:CYBNCybin IncSEDAR Final Short Form ProspectusSEDAR Final Short Form Prospectus
2023-06-16 13:47C:CYBNCybin Inc0.36SEDAR Preliminary Short Form ProspectusSEDAR Preliminary Short Form Prospectus
2023-06-08 11:51C:CYBNCybin Inc0.31News ReleaseCybin expects CYB003, CYB004 trial data in Q3 2023
2023-06-05 12:32C:CYBNCybin Inc0.37News ReleaseCybin R&D officer, innovations officer to step down
2023-05-24 10:07C:CYBNCybin Inc0.395News ReleaseCybin begins first-in-human dosing of CYB004 in trial
2023-05-09 10:49C:CYBNCybin Inc0.40News ReleaseCybin doses last subject in Part B of CYB004-E trial